ASIA-PACIFIC RAT MODEL MARKET FORECAST 2017-2025
KEY FINDINGS
The Asia-Pacific market is anticipated to grow at a CAGR of 9.11 % for the forecast period of 2017-2025 and is expected to generate a revenue of $203689 thousand by the year 2025. The rising demand for research activities in the Asia-Pacific countries has increased the opportunities for the market by many folds.
MARKET INSIGHTS
The Asia-Pacific market is rapidly flourishing because of major drivers like supportive R&D incentive schemes for Contract Research Organizations and biotechnological complies along with the booming pharmaceutical sectors in regional countries such as Australia, India, and China. At present, India has the third largest pharmaceutical industry in the world whereas, China is presently the second largest investor in research & development globally and it is expected to overtake US research & development investments by the year 2023.At present, the toxicology application is dominating the current market scene. However, the oncology market is fast growing owing to the increasing number of cancer cases worldwide and is estimated to grow at a CAGR of 11.17 % by 2025.On the basis of the market segmentation done by type, the genetically engineered outbred type is seemingly a fast emerging market growing at a CAGR of 11.36% whereas the other types such as Surgically Modified Rats, Inbred, Hybrid and Immune-Deficient Rat and are expected to grow at a CAGR of 9.66%, 8.63%, 10.11% and 9.84% respectively during the forecast period. On the basis of the market segmentation done by component, the services sector is predicted to lead the market and is predicted to grow faster with a CAGR of 10.45% by the end of the forecast period.
COMPETITIVE INSIGHTS
The leading companies players in the Asia-Pacific Rat Model market are Covance Inc. (LabCorp holding company), Biomedical research model Inc., Genoway s. A., Charles River Laboratories Inc, Harlan Laboratories, Inc. (envigo, Inc. Holding company), Janvier labs, sage labs Inc. (horizon discovery group plc holding company), Transposagen Biopharmaceuticals Inc bio-pharmaceuticals Inc. Transviragen Inc., Hera Biolabs Inc., Taconic Biosciences Ltd Oncodesign s.a., Cyagen biosciences Inc., Vivo Biotech and Clea Japan.
The Asia-Pacific market is anticipated to grow at a CAGR of 9.11 % for the forecast period of 2017-2025 and is expected to generate a revenue of $203689 thousand by the year 2025. The rising demand for research activities in the Asia-Pacific countries has increased the opportunities for the market by many folds.
MARKET INSIGHTS
The Asia-Pacific market is rapidly flourishing because of major drivers like supportive R&D incentive schemes for Contract Research Organizations and biotechnological complies along with the booming pharmaceutical sectors in regional countries such as Australia, India, and China. At present, India has the third largest pharmaceutical industry in the world whereas, China is presently the second largest investor in research & development globally and it is expected to overtake US research & development investments by the year 2023.At present, the toxicology application is dominating the current market scene. However, the oncology market is fast growing owing to the increasing number of cancer cases worldwide and is estimated to grow at a CAGR of 11.17 % by 2025.On the basis of the market segmentation done by type, the genetically engineered outbred type is seemingly a fast emerging market growing at a CAGR of 11.36% whereas the other types such as Surgically Modified Rats, Inbred, Hybrid and Immune-Deficient Rat and are expected to grow at a CAGR of 9.66%, 8.63%, 10.11% and 9.84% respectively during the forecast period. On the basis of the market segmentation done by component, the services sector is predicted to lead the market and is predicted to grow faster with a CAGR of 10.45% by the end of the forecast period.
COMPETITIVE INSIGHTS
The leading companies players in the Asia-Pacific Rat Model market are Covance Inc. (LabCorp holding company), Biomedical research model Inc., Genoway s. A., Charles River Laboratories Inc, Harlan Laboratories, Inc. (envigo, Inc. Holding company), Janvier labs, sage labs Inc. (horizon discovery group plc holding company), Transposagen Biopharmaceuticals Inc bio-pharmaceuticals Inc. Transviragen Inc., Hera Biolabs Inc., Taconic Biosciences Ltd Oncodesign s.a., Cyagen biosciences Inc., Vivo Biotech and Clea Japan.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. IMPROVEMENT IN GENOME EDITING
4.1.2. FAST AND INCREASING AVAILABILITY IN RAT TRANSGENIC
4.1.3. INCREASING PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES R&D
4.2. MARKET RESTRAINTS
4.2.1. PRACTICE OF ANIMALS IN RESEARCH IS CONSIDERED UNETHICAL
4.2.2. FLUCTUATING RULES AND REGULATION ON ANIMAL TESTING
4.2.3. USE OF ZEBRA FISH IN RESEARCH IS THE GROWING MODEL
4.2.4. IN VITRO AND ALTERNATIVE TESTING TECHNIQUES MODELS FOR RESEARCH
4.3. MARKET OPPORTUNITIES
4.3.1. RISING DEMAND OF RAT MODEL FOR RESEARCH ACTIVITIES FROM EMERGENT ECONOMIES
4.3.2. PERSONALIZED MEDICINE ESTABLISHED TO SURGE DEMAND
4.3.3. ESCALATION IN MONOCLONAL ANTIBODY CREATION
4.4. MARKET CHALLENGES
4.4.1. RAT MODEL IS HIGHLY EXPENSIVE
5. MARKET SEGMENTATION
5.1. BY RAT MODEL TYPES
5.1.1. INBRED RATS
5.1.2. KNOCKOUT/GENETICALLY ENGINEERED RATS
5.1.3. HYBRID/CONGENIC RATS
5.1.4. OUTBRED RATS
5.1.5. IMMUNE-DEFICIENT RATS
5.1.6. CONDITIONED/SURGICALLY MODIFIED RATS
5.2. BY COMPONENTS
5.2.1. TECHNOLOGY
5.2.1.1. NUCLEAR TRANSFERASE TECHNOLOGY
5.2.1.2. MICROINJECTION
5.2.1.3. EMBRYONIC STEM CELL INJECTION
5.2.1.4. OTHER TECHNOLOGY
5.2.2. SERVICES
5.2.3. RAT CARE PRODUCTS
5.2.3.1. FEED
5.2.3.2. BEDDING
5.2.3.3. CAGES
5.2.3.4. OTHER CARE PRODUCTS
5.3. BY APPLICATION
5.3.1. DIABETES
5.3.2. TOXICOLOGY
5.3.3. ONCOLOGY
5.3.4. IMMUNOLOGY & INFLAMMATION
5.3.5. OTHER
6. KEY ANALYTICS
6.1. PORTERS 5 FORCE MODEL
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTE PRODUCT
6.1.3. BARGAINING POWER OF BUYERS
6.1.4. BARGAINING POWER OF SUPPLIERS
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. PESTEL ANALYSIS
6.3. VALUE CHAIN ANALYSIS
6.4. OPPORTUNITY MATRIX
6.5. REGULATORY FRAMEWORK
6.6. ESTIMATION ANALYSIS
6.6.1. GLOBAL BIOTECH INVESTMENT
6.6.2. BIOTECHNOLOGY FIRMS ACROSS COUNTRIES
6.6.3. GLOBAL PHARMACEUTICAL RESEARCH & DEVELOPMENT EXPENDITURE
6.6.4. GLOBAL BIOTECH R&D EXPENDITURE
6.7. KEY BUYING CRITERIA
6.7.1. HIGH ACCURACY
6.7.2. HIGH EFFICACY
6.7.3. QUALITY OF OPERATING PROCEDURE
6.7.4. PRICE
7. GEOGRAPHICAL ANALYSIS
7.1. ASIA PACIFIC
7.2. CHINA
7.3. INDIA
7.4. JAPAN
7.5. SOUTH KOREA
7.6. AUSTRALIA
7.7. REST OF ASIA-PACIFIC
8. COMPETITIVE ANALYSIS
8.1. KEY STRATEGIES AND ANALYSIS
8.1.1. MERGER & ACQUISITION (M&A)
8.1.2. COLLABORATION & PARTNERSHIPS
8.1.3. INVESTMENT / PRODUCT LAUNCH
8.2. MARKET SHARE
8.3. TOP COMPANY ANALYSIS
8.4. LIST OF M&A
8.5. COLLABORATION & PARTNERSHIP
8.6. LIST OF PRODUCT LAUNCHES
9. COMPANY PROFILE
9.1. BIOMEDICAL RESEARCH MODEL INC.
9.1.1. COMPANY OVERVIEW
9.1.2. PRODUCT PORTFOL
9.1.3. SCOT ANALYSIS
9.2. CHARLES RIVER LABORATORIES INC.
9.2.1. COMPANY OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. KEY INNOVATION SECTOR
9.2.4. STRATEGIC INITIATIVES
9.2.5. SCOT ANALYSIS
9.3. COVANCE INC. (LABCORP HOLDING COMPANY)
9.3.1. COMPANY OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. KEY INNOVATION SECTOR
9.3.4. STRATEGIC INITIATIVES
9.3.5. SCOT ANALYSIS
9.4. GENOWAY S. A.
9.4.1. COMPANY OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. KEY INNOVATION SECTOR
9.4.4. STRATEGIC INITIATIVES
9.4.5. SCOT ANALYSIS
9.5. HARLAN LABORATORIES, INC. (ENVIGO, INC. HOLDING COMPANY)
9.5.1. COMPANY OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. STRATEGIC INITIATIVES
9.5.4. SCOT ANALYSIS
9.6. JANVIER LABS
9.6.1. COMPANY OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.7. SAGE LABS INC(HORIZON DISCOVERY GROUP PLC HOLDING COMPANY)
9.7.1. COMPANY OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC INITIATIVES
9.7.4. SCOT ANALYSIS
9.8. TACONIC BIOSCIENCES
9.8.1. COMPANY OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. KEY INNOVATION SECTOR
9.8.4. STRATEGIC INITIATIVES
9.8.5. SCOT ANALYSIS
9.9. TRANSPOSAGEN BIOPHARMACEUTICALS INC
9.9.1. COMPANY OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. KEY INNOVATION SECTOR
9.9.4. STRATEGIC INITIATIVES
9.9.5. SCOT ANALYSIS
9.10. TRANSVIRAGEN INC.
9.10.1. COMPANY OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. SCOT ANALYSIS
9.11. HERA BIOLABS INC.
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. KEY INNOVATION SECTOR
9.11.4. STRATEGIC INITIATIVE
9.11.5. SCOT ANALYSIS
9.12. ONCODESIGN S.A.
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. KEY INNOVATION SECTOR
9.12.4. STRATEGIC INITIATIVE
9.12.5. SCOT ANALYSIS
9.13. CYAGEN BIOSCIENCES INC.
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. KEY INNOVATION SECTOR
9.13.4. STRATEGIC INITIATIVE
9.13.5. SCOT ANALYSIS
9.14. VIVO BIOTECH LTD.
9.14.1. COMPANY OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. STRATEGIC INITIATIVES
9.14.4. SCOT ANALYSIS
9.15. CLEA JAPAN
9.15.1. COMPANY OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. STRATEGIC INITIATIVES
9.15.4. KEY INNOVATION SECTOR
9.15.5. SCOT ANALYSIS
9.16. TRANSVIRAGEN, INC.
9.16.1. COMPANY OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. STRATEGIC INITIATIVES
9.16.4. KEY INNOVATION SECTOR
9.16.5. SCOT ANALYSIS
9.17. BIOMERE
9.17.1. COMPANY OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. STRATEGIC INITIATIVES
9.17.4. KEY INNOVATION SECTOR
9.17.5. SCOT ANALYSIS
9.18. LABORATORY CORPORATION OF AMERICA HOLDINGS
9.18.1. COMPANY OVERVIEW
9.18.2. PRODUCT PORTFOLIO
9.18.3. STRATEGIC INITIATIVES
9.18.4. KEY INNOVATION SECTOR
9.18.5. SCOT ANALYSIS
TABLE LIST
TABLE 1 ASIA PACIFIC RAT MODEL MARKET 2017-2025 ($ THOUSAND)
TABLE 2 BENEFITS OF RATS
TABLE 3 ASIA PACIFIC RATS MODEL MARKET BY RAT TYPES 2017-2025 ($ THOUSAND)
TABLE 4 EXAMPLES OF INBRED RATS AND THERE RESEARCH APPLICATIONS
TABLE 5 ASIA PACIFIC INBRED RATS TYPE 2017-2025 ($ THOUSAND)
TABLE 6 ASIA PACIFIC GENETICALLY ENGINEERED RATS MARKET 2017-2025($ THOUSAND)
TABLE 7 ASIA PACIFIC HYBRID RATS MARKET 2017-2025 ($ THOUSAND)
TABLE 8 EXAMPLES OF OUTBRED RATS AND THERE RESEARCH APPLICATIONS
TABLE 9 ASIA PACIFIC OUTBRED RATS MARKET 2017-2025 ($ THOUSAND)
TABLE 10 ASIA PACIFIC IMMUNE DEFICIET RATS MARKET 2017-2025 ($ THOUSAND)
TABLE 11 ASIA PACIFIC SURGICALLY MODIFIED RATS MARKET 2017-2025 ($ THOUSAND)
TABLE 12 ASIA PACIFIC RATS MODEL MARKET BY COMPONENTS 2017-2025 ($ THOUSAND)
TABLE 13 ASIA PACIFIC RATS MODEL MARKET BY TECHNOLOGY 2017-2025 ($ THOUSAND)
TABLE 14 ASIA PACIFIC NUCLEAR TRANSFER TECHNOLOGY 2017-2025 ($ THOUSAND)
TABLE 15 ASIA PACIFIC MICRO INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
TABLE 16 ASIA PACIFIC EMBRYONIC STEM CELL INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
TABLE 17 ASIA PACIFIC OTHER TECHNOLOGY RAT MODEL MARKET 2017-2025 ($ THOUSAND)
TABLE 18 ASIA PACIFIC RAT MODEL SERVICES MARKET 2017-2025 ($ THOUSAND)
TABLE 19 ASIA PACIFIC RAT MODEL MARKET BY RAT CARE PRODUCTS 2017-2025 ($ THOUSAND)
TABLE 20 ASIA PACIFIC RAT FEED MARKET 2017-2025 ($ THUSAND)
TABLE 21 POPULAR FOODS FOR RATS
TABLE 22 ASIA PACIFIC RAT BEDDING MARKET 2017-2025 ($ THUSAND)
TABLE 23 ASIA PACIFIC RAT CAGES MARKET 2017-2025 ($ THOUSAND)
TABLE 24 ASIA PACIFIC RAT CARE OTHERS MARKET 2017-2025 ($ THOUSAND)
TABLE 25 ASIA PACIFIC RAT MODEL MARKET BY APPLICATION 2017-2025($ THOUSAND)
TABLE 26 ASIA PACIFIC DIABETES RAT MODEL MARKET 2017-2025($ THOUSAND)
TABLE 27 ASIA PACIFIC ONCOLOGY RAT MODEL MARKET 2017-2025($ THOUSAND)
TABLE 28 ASIA PACIFIC IMMUNOLOGY & INFLAMMATION RAT MODEL MARKET 2017-2025 ($ THOUSAND)
TABLE 29 ASIA PACIFIC OTHER RAT MODEL MARKET 2017-2025 ($ THOUSAND)
TABLE 30 ASIA PACIFIC RAT MODEL MARKET 2017-2025 ($ MILLION)
TABLE 31 ASIA PACIFIC RAT MODEL MARKET BY COUNTRY 2017-2025 ($ THOUSAND)
TABLE 32 SNAPSHOTS OF FEDERAL R&D INCENTIVES FOR CHINESE PHARMACEUTICAL COMPANIES & CROS
TABLE 33 SUMMARY OF FEDERAL R&D INCENTIVES FOR PHARMACEUTICAL COMPANIES & CROS IN INDIA
TABLE 34 SUMMARY OF FEDERAL R&D INCENTIVES FOR AUSTRALIAN PHARMACEUTICAL COMPANIES & CROS
FIGURES LIST
FIGURE 1 ASIA PACIFIC RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 2 TOP COMPANIES BASED ON IN VITRO DIAGNOSTICS REVENUE IN 2016 ($ MILLION)
FIGURE 3 HEALTHCARE EXPENDITURE OF DEVELOPING ECONOMIES AS % OF THEIR GDP 2016
FIGURE 4 ASIA PACIFIC RATS MODEL MARKET BY INBRED RATS TYPE 2017-2025 ($ THOUSAND)
FIGURE 5 ASIA PACIFIC RATS MODEL MARKET BY GENETICALLY ENGINEERED RATS 2017-2025 ($ THOUSAND)
FIGURE 6 ASIA PACIFIC RATS MODEL MARKET BY HYBRID RATS TYPE 2017-2025 ( $ THOUSAND)
FIGURE 7 ASIA PACIFIC RATS MODEL MARKET BY OUTBRED RATS 2017-2025 ($ THOUSAND)
FIGURE 8 ASIA PACIFIC RATS MODEL MARKET BY IMMUNE DEFICIENT RATS 2017-2025 ($ THOUSAND)
FIGURE 9 ASIA PACIFIC RATS MODEL MARKET BY SURGICALLY MODIFIED RATS 2017-2025 ($ THOUSAND)
FIGURE 10 ASIA PACIFIC RATS MODEL MARKET BY TECHNOLOGY 2017-2025 ($ THOUSANDS)
FIGURE 11 ASIA PACIFIC RATS MODEL MARKET BY NUCLEAR TRANSFER TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 12 ASIA PACIFIC RATS MODEL MARKET BY MICRO INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 13 ASIA PACIFIC RATS MODEL MARKET BY EMBRYONIC STEM CELL INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 14 ASIA PACIFIC RATS MODEL MARKET BY OTHER TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 15 RAT CARE PRODUCTS BY TYPE 2016 (%)
FIGURE 16 ASIA PACIFIC RAT CARE PRODUCT MARKET BY FEED 2017-2025 ($ THOUSAND)
FIGURE 17 ASIA PACIFIC RAT CARE PRODUCT MARKET BY BEDDING 2017-2025 ($ THOUSAND)
FIGURE 18 ASIA PACIFIC RAT CARE PRODUCT MARKET BY CAGES 2017-2025 ($ THOUSAND)
FIGURE 19 ASIA PACIFIC RAT MODEL MARKET BY DIABETES 2017-2025($ THOUSAND)
FIGURE 20 PERCENTAGE OF DIABETES IN WORLD ADULT POPULATION IN 1980, 2015 AND 2040
FIGURE 21 ASIA PACIFIC RAT MODEL MARKET BY TOXICOLOGY 2017-2025($ THOUSAND)
FIGURE 22 ASIA PACIFIC TOXICOLOGY RAT MODEL MARKET 2017-2025($ THOUSAND)
FIGURE 23 ASIA PACIFIC RAT MODEL MARKET BY ONCOLOGY 2017-2025($ THOUSAND)
FIGURE 24 INCREASING COSTS OF ONCOLOGY THERAPEUTICS AND SUPPORTIVE CARE DRUGS ($ BILLION)
FIGURE 25 ASIA PACIFIC RAT MODEL MARKET BY IMMUNOLOGY & INFLAMMATION 2017-2025 ($ THOUSAND)
FIGURE 26 ASIA PACIFIC RAT MODEL MARKET BY OTHER 2017-2025 ($ THOUSAND)
FIGURE 27 PORTERS 5 FORCE MODEL OF RAT MODEL
FIGURE 28 ASIA PACIFIC RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 29 CHINESE PHARMACEUTICAL MARKET 2015-2020 ($ BILLION)
FIGURE 30 CHINA RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 31 BUDGET ALLOCATION FOR DEPARTMENT OF SCIENCE AND TECHNOLOGY ($ MILLION)
FIGURE 32 INDIA RAT MODEL MARKET 2017-2025 ($THOUSAND)
FIGURE 33 GROSS EXPENDITURE ON R&D IN JAPAN 2014-2016 ($ BILLION)
FIGURE 34 JAPAN RAT MODEL MARKET 2017-2025 ($THOUSAND)
FIGURE 35 SOUTH KOREA’S PHARMACEUTICAL MARKET 2016-2020 ($ BILLION)
FIGURE 36 SOUTH KOREA RAT MODEL MARKET 2017-2025 ($THOUSAND)
FIGURE 37 AUSTRALIA RAT MODEL MARKET 2017-2025 ($THOUSAND)
FIGURE 38 REST OF ASIA-PACIFIC RAT MODEL MARKET 2017-2025 ($THOUSAND)
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
4. MARKET DETERMINANTS
4.1. MARKET DRIVERS
4.1.1. IMPROVEMENT IN GENOME EDITING
4.1.2. FAST AND INCREASING AVAILABILITY IN RAT TRANSGENIC
4.1.3. INCREASING PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES R&D
4.2. MARKET RESTRAINTS
4.2.1. PRACTICE OF ANIMALS IN RESEARCH IS CONSIDERED UNETHICAL
4.2.2. FLUCTUATING RULES AND REGULATION ON ANIMAL TESTING
4.2.3. USE OF ZEBRA FISH IN RESEARCH IS THE GROWING MODEL
4.2.4. IN VITRO AND ALTERNATIVE TESTING TECHNIQUES MODELS FOR RESEARCH
4.3. MARKET OPPORTUNITIES
4.3.1. RISING DEMAND OF RAT MODEL FOR RESEARCH ACTIVITIES FROM EMERGENT ECONOMIES
4.3.2. PERSONALIZED MEDICINE ESTABLISHED TO SURGE DEMAND
4.3.3. ESCALATION IN MONOCLONAL ANTIBODY CREATION
4.4. MARKET CHALLENGES
4.4.1. RAT MODEL IS HIGHLY EXPENSIVE
5. MARKET SEGMENTATION
5.1. BY RAT MODEL TYPES
5.1.1. INBRED RATS
5.1.2. KNOCKOUT/GENETICALLY ENGINEERED RATS
5.1.3. HYBRID/CONGENIC RATS
5.1.4. OUTBRED RATS
5.1.5. IMMUNE-DEFICIENT RATS
5.1.6. CONDITIONED/SURGICALLY MODIFIED RATS
5.2. BY COMPONENTS
5.2.1. TECHNOLOGY
5.2.1.1. NUCLEAR TRANSFERASE TECHNOLOGY
5.2.1.2. MICROINJECTION
5.2.1.3. EMBRYONIC STEM CELL INJECTION
5.2.1.4. OTHER TECHNOLOGY
5.2.2. SERVICES
5.2.3. RAT CARE PRODUCTS
5.2.3.1. FEED
5.2.3.2. BEDDING
5.2.3.3. CAGES
5.2.3.4. OTHER CARE PRODUCTS
5.3. BY APPLICATION
5.3.1. DIABETES
5.3.2. TOXICOLOGY
5.3.3. ONCOLOGY
5.3.4. IMMUNOLOGY & INFLAMMATION
5.3.5. OTHER
6. KEY ANALYTICS
6.1. PORTERS 5 FORCE MODEL
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTE PRODUCT
6.1.3. BARGAINING POWER OF BUYERS
6.1.4. BARGAINING POWER OF SUPPLIERS
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. PESTEL ANALYSIS
6.3. VALUE CHAIN ANALYSIS
6.4. OPPORTUNITY MATRIX
6.5. REGULATORY FRAMEWORK
6.6. ESTIMATION ANALYSIS
6.6.1. GLOBAL BIOTECH INVESTMENT
6.6.2. BIOTECHNOLOGY FIRMS ACROSS COUNTRIES
6.6.3. GLOBAL PHARMACEUTICAL RESEARCH & DEVELOPMENT EXPENDITURE
6.6.4. GLOBAL BIOTECH R&D EXPENDITURE
6.7. KEY BUYING CRITERIA
6.7.1. HIGH ACCURACY
6.7.2. HIGH EFFICACY
6.7.3. QUALITY OF OPERATING PROCEDURE
6.7.4. PRICE
7. GEOGRAPHICAL ANALYSIS
7.1. ASIA PACIFIC
7.2. CHINA
7.3. INDIA
7.4. JAPAN
7.5. SOUTH KOREA
7.6. AUSTRALIA
7.7. REST OF ASIA-PACIFIC
8. COMPETITIVE ANALYSIS
8.1. KEY STRATEGIES AND ANALYSIS
8.1.1. MERGER & ACQUISITION (M&A)
8.1.2. COLLABORATION & PARTNERSHIPS
8.1.3. INVESTMENT / PRODUCT LAUNCH
8.2. MARKET SHARE
8.3. TOP COMPANY ANALYSIS
8.4. LIST OF M&A
8.5. COLLABORATION & PARTNERSHIP
8.6. LIST OF PRODUCT LAUNCHES
9. COMPANY PROFILE
9.1. BIOMEDICAL RESEARCH MODEL INC.
9.1.1. COMPANY OVERVIEW
9.1.2. PRODUCT PORTFOL
9.1.3. SCOT ANALYSIS
9.2. CHARLES RIVER LABORATORIES INC.
9.2.1. COMPANY OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. KEY INNOVATION SECTOR
9.2.4. STRATEGIC INITIATIVES
9.2.5. SCOT ANALYSIS
9.3. COVANCE INC. (LABCORP HOLDING COMPANY)
9.3.1. COMPANY OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. KEY INNOVATION SECTOR
9.3.4. STRATEGIC INITIATIVES
9.3.5. SCOT ANALYSIS
9.4. GENOWAY S. A.
9.4.1. COMPANY OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. KEY INNOVATION SECTOR
9.4.4. STRATEGIC INITIATIVES
9.4.5. SCOT ANALYSIS
9.5. HARLAN LABORATORIES, INC. (ENVIGO, INC. HOLDING COMPANY)
9.5.1. COMPANY OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. STRATEGIC INITIATIVES
9.5.4. SCOT ANALYSIS
9.6. JANVIER LABS
9.6.1. COMPANY OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.7. SAGE LABS INC(HORIZON DISCOVERY GROUP PLC HOLDING COMPANY)
9.7.1. COMPANY OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC INITIATIVES
9.7.4. SCOT ANALYSIS
9.8. TACONIC BIOSCIENCES
9.8.1. COMPANY OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. KEY INNOVATION SECTOR
9.8.4. STRATEGIC INITIATIVES
9.8.5. SCOT ANALYSIS
9.9. TRANSPOSAGEN BIOPHARMACEUTICALS INC
9.9.1. COMPANY OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. KEY INNOVATION SECTOR
9.9.4. STRATEGIC INITIATIVES
9.9.5. SCOT ANALYSIS
9.10. TRANSVIRAGEN INC.
9.10.1. COMPANY OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. SCOT ANALYSIS
9.11. HERA BIOLABS INC.
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. KEY INNOVATION SECTOR
9.11.4. STRATEGIC INITIATIVE
9.11.5. SCOT ANALYSIS
9.12. ONCODESIGN S.A.
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. KEY INNOVATION SECTOR
9.12.4. STRATEGIC INITIATIVE
9.12.5. SCOT ANALYSIS
9.13. CYAGEN BIOSCIENCES INC.
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. KEY INNOVATION SECTOR
9.13.4. STRATEGIC INITIATIVE
9.13.5. SCOT ANALYSIS
9.14. VIVO BIOTECH LTD.
9.14.1. COMPANY OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. STRATEGIC INITIATIVES
9.14.4. SCOT ANALYSIS
9.15. CLEA JAPAN
9.15.1. COMPANY OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. STRATEGIC INITIATIVES
9.15.4. KEY INNOVATION SECTOR
9.15.5. SCOT ANALYSIS
9.16. TRANSVIRAGEN, INC.
9.16.1. COMPANY OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. STRATEGIC INITIATIVES
9.16.4. KEY INNOVATION SECTOR
9.16.5. SCOT ANALYSIS
9.17. BIOMERE
9.17.1. COMPANY OVERVIEW
9.17.2. PRODUCT PORTFOLIO
9.17.3. STRATEGIC INITIATIVES
9.17.4. KEY INNOVATION SECTOR
9.17.5. SCOT ANALYSIS
9.18. LABORATORY CORPORATION OF AMERICA HOLDINGS
9.18.1. COMPANY OVERVIEW
9.18.2. PRODUCT PORTFOLIO
9.18.3. STRATEGIC INITIATIVES
9.18.4. KEY INNOVATION SECTOR
9.18.5. SCOT ANALYSIS
TABLE LIST
TABLE 1 ASIA PACIFIC RAT MODEL MARKET 2017-2025 ($ THOUSAND)
TABLE 2 BENEFITS OF RATS
TABLE 3 ASIA PACIFIC RATS MODEL MARKET BY RAT TYPES 2017-2025 ($ THOUSAND)
TABLE 4 EXAMPLES OF INBRED RATS AND THERE RESEARCH APPLICATIONS
TABLE 5 ASIA PACIFIC INBRED RATS TYPE 2017-2025 ($ THOUSAND)
TABLE 6 ASIA PACIFIC GENETICALLY ENGINEERED RATS MARKET 2017-2025($ THOUSAND)
TABLE 7 ASIA PACIFIC HYBRID RATS MARKET 2017-2025 ($ THOUSAND)
TABLE 8 EXAMPLES OF OUTBRED RATS AND THERE RESEARCH APPLICATIONS
TABLE 9 ASIA PACIFIC OUTBRED RATS MARKET 2017-2025 ($ THOUSAND)
TABLE 10 ASIA PACIFIC IMMUNE DEFICIET RATS MARKET 2017-2025 ($ THOUSAND)
TABLE 11 ASIA PACIFIC SURGICALLY MODIFIED RATS MARKET 2017-2025 ($ THOUSAND)
TABLE 12 ASIA PACIFIC RATS MODEL MARKET BY COMPONENTS 2017-2025 ($ THOUSAND)
TABLE 13 ASIA PACIFIC RATS MODEL MARKET BY TECHNOLOGY 2017-2025 ($ THOUSAND)
TABLE 14 ASIA PACIFIC NUCLEAR TRANSFER TECHNOLOGY 2017-2025 ($ THOUSAND)
TABLE 15 ASIA PACIFIC MICRO INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
TABLE 16 ASIA PACIFIC EMBRYONIC STEM CELL INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
TABLE 17 ASIA PACIFIC OTHER TECHNOLOGY RAT MODEL MARKET 2017-2025 ($ THOUSAND)
TABLE 18 ASIA PACIFIC RAT MODEL SERVICES MARKET 2017-2025 ($ THOUSAND)
TABLE 19 ASIA PACIFIC RAT MODEL MARKET BY RAT CARE PRODUCTS 2017-2025 ($ THOUSAND)
TABLE 20 ASIA PACIFIC RAT FEED MARKET 2017-2025 ($ THUSAND)
TABLE 21 POPULAR FOODS FOR RATS
TABLE 22 ASIA PACIFIC RAT BEDDING MARKET 2017-2025 ($ THUSAND)
TABLE 23 ASIA PACIFIC RAT CAGES MARKET 2017-2025 ($ THOUSAND)
TABLE 24 ASIA PACIFIC RAT CARE OTHERS MARKET 2017-2025 ($ THOUSAND)
TABLE 25 ASIA PACIFIC RAT MODEL MARKET BY APPLICATION 2017-2025($ THOUSAND)
TABLE 26 ASIA PACIFIC DIABETES RAT MODEL MARKET 2017-2025($ THOUSAND)
TABLE 27 ASIA PACIFIC ONCOLOGY RAT MODEL MARKET 2017-2025($ THOUSAND)
TABLE 28 ASIA PACIFIC IMMUNOLOGY & INFLAMMATION RAT MODEL MARKET 2017-2025 ($ THOUSAND)
TABLE 29 ASIA PACIFIC OTHER RAT MODEL MARKET 2017-2025 ($ THOUSAND)
TABLE 30 ASIA PACIFIC RAT MODEL MARKET 2017-2025 ($ MILLION)
TABLE 31 ASIA PACIFIC RAT MODEL MARKET BY COUNTRY 2017-2025 ($ THOUSAND)
TABLE 32 SNAPSHOTS OF FEDERAL R&D INCENTIVES FOR CHINESE PHARMACEUTICAL COMPANIES & CROS
TABLE 33 SUMMARY OF FEDERAL R&D INCENTIVES FOR PHARMACEUTICAL COMPANIES & CROS IN INDIA
TABLE 34 SUMMARY OF FEDERAL R&D INCENTIVES FOR AUSTRALIAN PHARMACEUTICAL COMPANIES & CROS
FIGURES LIST
FIGURE 1 ASIA PACIFIC RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 2 TOP COMPANIES BASED ON IN VITRO DIAGNOSTICS REVENUE IN 2016 ($ MILLION)
FIGURE 3 HEALTHCARE EXPENDITURE OF DEVELOPING ECONOMIES AS % OF THEIR GDP 2016
FIGURE 4 ASIA PACIFIC RATS MODEL MARKET BY INBRED RATS TYPE 2017-2025 ($ THOUSAND)
FIGURE 5 ASIA PACIFIC RATS MODEL MARKET BY GENETICALLY ENGINEERED RATS 2017-2025 ($ THOUSAND)
FIGURE 6 ASIA PACIFIC RATS MODEL MARKET BY HYBRID RATS TYPE 2017-2025 ( $ THOUSAND)
FIGURE 7 ASIA PACIFIC RATS MODEL MARKET BY OUTBRED RATS 2017-2025 ($ THOUSAND)
FIGURE 8 ASIA PACIFIC RATS MODEL MARKET BY IMMUNE DEFICIENT RATS 2017-2025 ($ THOUSAND)
FIGURE 9 ASIA PACIFIC RATS MODEL MARKET BY SURGICALLY MODIFIED RATS 2017-2025 ($ THOUSAND)
FIGURE 10 ASIA PACIFIC RATS MODEL MARKET BY TECHNOLOGY 2017-2025 ($ THOUSANDS)
FIGURE 11 ASIA PACIFIC RATS MODEL MARKET BY NUCLEAR TRANSFER TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 12 ASIA PACIFIC RATS MODEL MARKET BY MICRO INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 13 ASIA PACIFIC RATS MODEL MARKET BY EMBRYONIC STEM CELL INJECTION TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 14 ASIA PACIFIC RATS MODEL MARKET BY OTHER TECHNOLOGY 2017-2025 ($ THOUSAND)
FIGURE 15 RAT CARE PRODUCTS BY TYPE 2016 (%)
FIGURE 16 ASIA PACIFIC RAT CARE PRODUCT MARKET BY FEED 2017-2025 ($ THOUSAND)
FIGURE 17 ASIA PACIFIC RAT CARE PRODUCT MARKET BY BEDDING 2017-2025 ($ THOUSAND)
FIGURE 18 ASIA PACIFIC RAT CARE PRODUCT MARKET BY CAGES 2017-2025 ($ THOUSAND)
FIGURE 19 ASIA PACIFIC RAT MODEL MARKET BY DIABETES 2017-2025($ THOUSAND)
FIGURE 20 PERCENTAGE OF DIABETES IN WORLD ADULT POPULATION IN 1980, 2015 AND 2040
FIGURE 21 ASIA PACIFIC RAT MODEL MARKET BY TOXICOLOGY 2017-2025($ THOUSAND)
FIGURE 22 ASIA PACIFIC TOXICOLOGY RAT MODEL MARKET 2017-2025($ THOUSAND)
FIGURE 23 ASIA PACIFIC RAT MODEL MARKET BY ONCOLOGY 2017-2025($ THOUSAND)
FIGURE 24 INCREASING COSTS OF ONCOLOGY THERAPEUTICS AND SUPPORTIVE CARE DRUGS ($ BILLION)
FIGURE 25 ASIA PACIFIC RAT MODEL MARKET BY IMMUNOLOGY & INFLAMMATION 2017-2025 ($ THOUSAND)
FIGURE 26 ASIA PACIFIC RAT MODEL MARKET BY OTHER 2017-2025 ($ THOUSAND)
FIGURE 27 PORTERS 5 FORCE MODEL OF RAT MODEL
FIGURE 28 ASIA PACIFIC RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 29 CHINESE PHARMACEUTICAL MARKET 2015-2020 ($ BILLION)
FIGURE 30 CHINA RAT MODEL MARKET 2017-2025 ($ THOUSAND)
FIGURE 31 BUDGET ALLOCATION FOR DEPARTMENT OF SCIENCE AND TECHNOLOGY ($ MILLION)
FIGURE 32 INDIA RAT MODEL MARKET 2017-2025 ($THOUSAND)
FIGURE 33 GROSS EXPENDITURE ON R&D IN JAPAN 2014-2016 ($ BILLION)
FIGURE 34 JAPAN RAT MODEL MARKET 2017-2025 ($THOUSAND)
FIGURE 35 SOUTH KOREA’S PHARMACEUTICAL MARKET 2016-2020 ($ BILLION)
FIGURE 36 SOUTH KOREA RAT MODEL MARKET 2017-2025 ($THOUSAND)
FIGURE 37 AUSTRALIA RAT MODEL MARKET 2017-2025 ($THOUSAND)
FIGURE 38 REST OF ASIA-PACIFIC RAT MODEL MARKET 2017-2025 ($THOUSAND)
